Jazz Pharma Ireland Ltd v. Tris Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Jazz Pharmaceuticals Ireland Limited (Ireland)
  • Defendant: Tris Pharma, Inc. (New Jersey)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-01740, D.N.J., 02/20/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant is a New Jersey corporation with a principal place of business in the district, conducts business in the state, and the district is a likely destination for the accused product.
• Core Dispute: Plaintiff alleges that Defendant's submission of a New Drug Application (NDA) for a generic version of Plaintiff's Xywav® drug product constitutes an act of infringement of fifteen patents related to gamma-hydroxybutyrate (GHB) compositions and methods of use.
• Technical Context: The technology concerns pharmaceutical compositions of oxybate (the anion of GHB), specifically mixed-salt formulations designed to treat sleep disorders such as narcolepsy and idiopathic hypersomnia while managing patients' total sodium intake.
• Key Procedural History: This action arises under the Hatch-Waxman Act following Defendant's submission of NDA No. 220138 to the U.S. Food and Drug Administration (FDA). Defendant provided Paragraph IV Certifications asserting that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by its proposed product. Plaintiff's counsel certifies that this matter is related to other consolidated cases involving Jazz and certain of the same patents, suggesting a history of litigation surrounding this patent portfolio.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,591,922 - "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders" (Issued Nov. 26, 2013)

• The Invention Explained:

  • Problem Addressed: The patent describes that existing gamma-hydroxybutyrate (GHB) therapy, commercially sold as Xyrem® (sodium oxybate), requires high levels of the drug U.S. Patent No. 10,195,168, col. 2:1-2 This results in a significant sodium intake for patients, which is undesirable for those with or at risk of hypertension, heart disease, or renal disease U.S. Patent No. 10,195,168, col. 2:2-5
  • The Patented Solution: The invention provides pharmaceutical compositions comprising a mixture of salts of GHB, using cations such as potassium, magnesium, and calcium in addition to or in place of sodium U.S. Patent No. 10,195,168, col. 2:40-45 U.S. Patent No. 10,195,168, abstract This approach aims to reduce the total sodium content of the medication while providing the therapeutic effects of GHB U.S. Patent No. 10,195,168, col. 2:35-39
  • Technical Importance: This innovation sought to make chronic GHB therapy safer for a broader patient population, particularly those for whom high sodium intake is a significant health concern.

• Key Claims at a Glance: The complaint does not assert specific claims, instead alleging infringement of "one or more claims" of the '922 patent Compl. ¶39

U.S. Patent No. 8,772,306 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters" (Issued July 8, 2014)

• The Invention Explained:

  • Problem Addressed: The patent addresses the safety and efficacy concerns arising from the co-administration of GHB with other drugs that inhibit monocarboxylate transporters (MCTs) U.S. Patent No. 10,213,400, col. 1:16-24 It notes that inhibitors such as valproate can increase the effect of GHB, while others like diclofenac can lower its effect, potentially leading to unsafe conditions for the patient U.S. Patent No. 10,213,400, abstract
  • The Patented Solution: The invention provides methods for safely administering GHB by adjusting the dosage when a patient is also receiving a concomitant administration of an MCT inhibitor. The claimed method involves reducing the GHB dose when co-administered with valproate and increasing it when co-administered with diclofenac to maintain the desired therapeutic effect U.S. Patent No. 10,213,400, col. 2:1-19
  • Technical Importance: This method provides a protocol to manage drug-drug interactions, enhancing the safety of GHB therapy for patients who require concomitant treatment with common drugs like valproate or NSAIDs.

• Key Claims at a Glance: The complaint does not assert specific claims, instead alleging infringement of "one or more claims" of the '306 patent Compl. ¶48

Multi-Patent Capsules

• U.S. Patent No. 8,901,173 (and related patents '107, '168, '258, '373, '102): Titled "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders," issued Dec. 2, 2014.

  • Technology Synopsis: These patents are part of the same family as the '922 patent and are directed to pharmaceutical compositions comprising mixed salts of GHB. The disclosed solutions aim to reduce sodium content by incorporating other cations (e.g., calcium, magnesium, potassium) to make the therapy suitable for patients with sodium-sensitive conditions U.S. Patent No. 10,195,168, col. 2:35-39
  • Asserted Claims: "one or more claims" Compl. ¶57 Compl. ¶75 Compl. ¶93 Compl. ¶111 Compl. ¶138 Compl. ¶147
  • Accused Features: The complaint alleges that Tris's Proposed Product, a version of the mixed-salt oxybate drug Xywav®, will infringe these composition claims Compl. ¶1 Compl. ¶19 Compl. ¶32

• U.S. Patent No. 9,050,302 (and related patents '426, '400, '181, '494, '446): Titled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued June 9, 2015.

  • Technology Synopsis: These patents are part of the same family as the '306 patent and claim methods of safely administering GHB to a patient. The methods involve adjusting the GHB dosage to account for drug-drug interactions when a patient is also taking a monocarboxylate transporter (MCT) inhibitor, such as valproate or diclofenac U.S. Patent No. 10,213,400, col. 1:16-24 U.S. Patent No. 10,213,400, abstract
  • Asserted Claims: "one or more claims" Compl. ¶66 Compl. ¶84 Compl. ¶102 Compl. ¶120 Compl. ¶129 Compl. ¶156
  • Accused Features: The complaint alleges that the labeling for Tris's Proposed Product will instruct or encourage the claimed methods of administration, including dosage adjustments, thereby inducing infringement Compl. ¶¶22-23

• U.S. Patent No. 12,138,233: Titled "Methods of treating idiopathic hypersomnia," issued Nov. 12, 2024.

  • Technology Synopsis: This patent claims methods of treating idiopathic hypersomnia (IH) by administering an oxybate composition, such as a mixed salt oxybate. The methods may specify particular dosing regimens (e.g., once nightly) for treating IH U.S. Patent No. 12,138,233, abstract
  • Asserted Claims: "one or more claims" Compl. ¶165
  • Accused Features: The complaint alleges that Tris's Proposed Product will be marketed for the treatment of idiopathic hypersomnia and that its labeling will induce infringement of the claimed methods Compl. ¶21

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is "Tris's Proposed Product," an oxybate drug product described in NDA No. 220138 submitted to the FDA Compl. ¶32

• Functionality and Market Context:

  • The complaint alleges Tris's Proposed Product is a version of Jazz's Xywav® drug product Compl. ¶1 Xywav® is identified as a drug product containing calcium, magnesium, potassium, and sodium oxybates Compl. ¶19
  • The product is intended for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy, and for the treatment of idiopathic hypersomnia Compl. ¶21
  • The complaint alleges that the labeling for Xywav®, and by extension the proposed labeling for Tris's product, instructs and encourages specific methods of administration, including dose modification when divalproex sodium (valproate) is concomitantly administered Compl. ¶¶22-23
  • Tris seeks FDA approval to manufacture and sell its product prior to the expiration of the patents-in-suit, positioning it as a generic competitor to Xywav® Compl. ¶1 Compl. ¶32
  • No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide sufficient detail for a claim-by-claim analysis of infringement. It does not assert specific claims or provide claim charts, instead alleging infringement of "one or more" claims of each patent-in-suit Compl. ¶37 Compl. ¶46 The infringement theory must be inferred from the general allegations.

• Narrative Infringement Theory (Composition Patents, e.g., '922 Patent): The complaint alleges that Tris's Proposed Product is a version of Xywav®, which is a mixed-salt oxybate drug Compl. ¶1 Compl. ¶19 The theory of direct infringement appears to be that the chemical composition of Tris's Proposed Product, as specified in its NDA, will fall within the scope of one or more of the composition claims of the '922 patent and its family members.

• Narrative Infringement Theory (Method Patents, e.g., '306 Patent): The complaint alleges that Tris, upon FDA approval, will induce and contribute to infringement Compl. ¶¶49-50 The basis for this theory appears to be that the proposed labeling for Tris's product will instruct physicians and patients to administer the drug in a manner that practices the patented methods. This includes administering it for the treatment of narcolepsy or idiopathic hypersomnia Compl. ¶21 and modifying the dose when co-administered with MCT inhibitors like valproate Compl. ¶22 These instructions are present on the label for the reference drug, Xywav® Compl. ¶¶21-23

• Identified Points of Contention:

  • Factual & Scope Questions: For the composition patents, a central question will be whether the specific formulation in Tris's NDA-including the identity and concentration of salts and any excipients-meets all the limitations of any asserted claims from the '922 patent family.
  • Inducement Questions: For the method patents, a key issue will be whether Tris's proposed product labeling will contain instructions or recommendations that encourage, recommend, or promote the performance of the patented methods of administration and dosage adjustments, thereby establishing the requisite intent for induced infringement.

V. Key Claim Terms for Construction

The complaint does not identify any specific asserted claims from the patents-in-suit, which precludes an analysis of key terms that may be central to claim construction.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all fifteen patents-in-suit (Compl. ¶¶40-41; Compl. ¶¶49-50). The allegations of inducement are based on the belief that Tris "will intentionally encourage acts of direct infringement" with knowledge of the patents, which may be supported by the instructions for use in the proposed product's labeling Compl. ¶40 Compl. ¶49 The allegations of contributory infringement are based on the assertion that Tris's Proposed Product is "especially adapted for a use that infringes" and has "no substantial non-infringing use" Compl. ¶41 Compl. ¶50
• Willful Infringement: While the term "willful" is not used, the complaint alleges for each count that the case is "exceptional" and seeks an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶44 Compl. ¶53 This claim is predicated on Tris's pre-suit knowledge of the patents, evidenced by its submission of Paragraph IV Certifications to the FDA and its notice letter to Jazz Compl. ¶¶34-35

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of compositional identity: Does the specific chemical formulation of Tris's Proposed Product, as defined in its confidential NDA submission, literally meet the limitations of any of the asserted claims in Jazz's portfolio of composition patents? This will likely require a detailed factual comparison of salt ratios, concentrations, and other formulation ingredients.
• A second core issue will be one of inducement via labeling: Will the FDA-approved label for Tris's product contain instructions that direct or encourage physicians and patients to perform the patented methods of use, including for specific disorders like idiopathic hypersomnia and with specific dosage adjustments for co-administered drugs, thereby satisfying the legal requirements for induced infringement?
• A third, and likely dispositive, area of dispute will be patent validity. Tris's Paragraph IV certification alleges the patents-in-suit are invalid and/or unenforceable Compl. ¶34 Consequently, a key focus of the litigation will be whether the claims of Jazz's fifteen patents can withstand challenges based on prior art and other validity-related defenses.